Skip to content

Ionis Pharmaceuticals IONS Debt Securities Available For Sale Accumulated Gross Unrealized Loss Before Tax Noncurrent

Debt Securities Available For Sale Accumulated Gross Unrealized Loss Before Tax Noncurrent at other companies

Chimera Investment Corp. logo
Chimera Investment Corp.CIM
$113.09M-2.6%
PNC Financial Services logo
PNC Financial ServicesPNC
$1.14B-45.8%
BK
BKBK
$3.64B-42.6%
Duke Energy logo
Duke EnergyDUK
$150M-19.8%
RPM International logo
RPM InternationalRPM
$2.16M
IES
IES Holdings, Inc.IESC
$0+100%

Other financials

Income statement

See full
Revenue$246.1M+87.0%
Gross profit$243.1M+86.8%
Operating income-$117.4M+20.0%
Net income-$92.5M+37.0%
EPS (diluted)-$0.56+39.8%

Balance sheet

See full
Cash & equivalents$173.4M-34.4%
Total debt$691.7M+334%
Total equity$491.4M+3.3%
Total assets$3.4B+22.6%

Cash flow

See full
Operating cash flow-$792.8M-426%
CapEx$21.8M+73.0%
Free cash flow-$814.6M-399%

Valuation

See full
Market cap$12.25B+159%
Enterprise value$12.77B+175%
P/S11.6×+5.0×

Profitability

See full
Gross margin98.4%-0.2pp
Operating margin-33.3%-11.0pp
Net margin-30.9%-10.5pp
FCF margin-77.4%+35.3pp

Returns & leverage

See full
Return on equity-67.6%-20.3pp
Debt / equity1.4×+1.1×
Current ratio4.1×-5.6×

Where this comes from

Reported directly by Ionis Pharmaceuticals in its filing.

Tagged under the XBRL concept ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent.

The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ionis Pharmaceuticals's debt securities available for sale accumulated gross unrealized loss before tax noncurrent.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ionis Pharmaceuticals's debt securities available for sale accumulated gross unrealized loss before tax noncurrent?
Ionis Pharmaceuticals (IONS) reported debt securities available for sale accumulated gross unrealized loss before tax noncurrent of $2.14M in Q1 2026.
How has Ionis Pharmaceuticals's debt securities available for sale accumulated gross unrealized loss before tax noncurrent changed year-over-year?
Ionis Pharmaceuticals's debt securities available for sale accumulated gross unrealized loss before tax noncurrent increased by 81.7% year-over-year, from $1.18M to $2.14M.
What is the long-term trend for Ionis Pharmaceuticals's debt securities available for sale accumulated gross unrealized loss before tax noncurrent?
Over 4 years (2021 to 2025), Ionis Pharmaceuticals's debt securities available for sale accumulated gross unrealized loss before tax noncurrent has grown at a -52.6% compound annual growth rate (CAGR), from $3.97M to $201K.
What does debt securities available for sale accumulated gross unrealized loss before tax noncurrent mean?
The total unrealized loss on non-current debt investments based on current market prices.
How do you interpret debt securities available for sale accumulated gross unrealized loss before tax noncurrent?
An increase indicates potential valuation pressure on the company's long-term debt portfolio due to market factors.
How does debt securities available for sale accumulated gross unrealized loss before tax noncurrent compare across companies?
Standard risk metric for long-term treasury assets across the industry.